GenCurix and DropFlex Companion Diagnostic Products Used to Predict Lung Cancer Treatment Response

GenCurix announced on the 12th that it used its 'Dropplex companion diagnostic product' in the update of the clinical trial 'LASER201' research results for Lekraza by Yuhan Corporation. The Dropplex companion diagnostic product analyzed the relationship between ctDNA monitoring in patients' blood and overall survival.

The research team conducted ctDNA mutation monitoring tests in the blood before treatment, at the 3rd cycle, and at the 5th cycle for 78 patients receiving Lekraza using GenCurix's diagnostic product. The study results showed that the patient group in which the previously detected EGFR mutation was no longer detected in ctDNA after treatment had better outcomes in key efficacy indicators such as disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared to the group where the mutation was still detected.

The company explained that the study proved Dropplex to be a diagnostic product capable of predicting treatment response through ctDNA monitoring in lung cancer patients receiving EGFR TKI therapy. The diagnostic product, which can detect 107 EGFR mutations, completed manufacturing approval from the Ministry of Food and Drug Safety last year and is currently used for diagnostic testing in clinical settings.

GenCurix Research Director Mi-ran Kang said, "The Dropplex companion diagnostic product has been proven to be useful not only for diagnosis but also for evaluating treatment efficacy and monitoring recurrence," adding, "We will use this as an opportunity to expand clinical applicability and enter overseas markets."